Intercept superstar: revenues exceeding estimates, solid plans and shares rise 10%

US-based biotech Intercept Pharmaceuticals yesterday announced its third quarter results. Investors were satisfied, indeed Intercept’s shares rose by 10% over few hours. Intercept’s main asset is undoubtedly Ocaliva (obeticholic acid), approved for the treatment of  primary biliary cholangitis